Laura Moran
Partner
Litigation
Laura
Moran
Laura
Moran
Partner
Litigation
Laura advises pharmaceutical and life sciences companies on a wide range of intellectual property and business-critical matters. With extensive experience litigating complex patent disputes—including Hatch-Waxman litigation, inter partes review proceedings, and IP-related arbitrations—Laura is known for guiding clients through high-stakes conflicts in federal courts, before the Patent Trial and Appeal Board, and at the Federal Circuit. Her ability to translate complex technical issues into clear legal and business guidance makes her a valued partner to clients at all stages of growth.
Laura has deep experience managing large-scale discovery and coordinating cross-functional case teams. She routinely oversees litigation portfolios for leading life sciences companies and is recognized for her collaborative approach and precise execution.
In addition to her litigation practice, Laura counsels clients on pre-litigation risk, IP strategy, and patent-related due diligence.
Committed to service and talent development, Laura maintains an active pro bono practice and has served as a Recruiting Partner for the firm’s New York and Washington, D.C. offices.
- Represented Novo Nordisk in a multidistrict patent infringement suit against six generic pharmaceutical manufacturers concerning Novo Nordisk’s best-selling type 2 diabetes therapy Ozempic®, which resulted in favorable confidential settlements on the eve of trial.
- Successful representation of Novo Nordisk in patent infringement lawsuits brought against six ANDA filers concerning Novo Nordisk’s weight-loss treatment Saxenda®.
- Represented Novo Nordisk in a series of Hatch-Waxman patent litigations relating to its blockbuster type 2 diabetes drug Victoza®. Prevailing in claim construction proceedings helped lead to favorable confidential settlements in each matter.
- Represented Pfizer and UCB in a series of District Court and PTAB trials concerning the drug Toviaz®. In the first trial against five defendants, the District Court ruled in Pfizer and UCB’s favor on all issues. In the second trial, the District Court ruled in Pfizer and UCB’s favor on all issues immediately upon the close of evidence. The PTAB upheld all challenged claims and the Federal Circuit affirmed.
- Represented Novo Nordisk as patent owner in an inter partes review filed by a competitor concerning methods of nanofiltering recombinant therapeutic proteins. The PTAB upheld all challenged claims in Novo Nordisk’s patent.
- Represented Swiss biopharmaceutical company IBSA in Hatch-Waxman litigations concerning its products Flector® and Tirosint®.
- Successful trial and appellate representation of UCB in a suit brought by generic manufacturer Apotex, alleging that UCB’s Univasc® and Uniretic® high blood pressure medications infringed Apotex’s patented method of manufacture. The district court found in UCB’s favor on all defenses, including inequitable conduct. The Federal Circuit affirmed unanimously, and the district court awarded UCB its legal fees.
*Includes experience from a previous firm
- Represented Novo Nordisk in a multidistrict patent infringement suit against six generic pharmaceutical manufacturers concerning Novo Nordisk’s best-selling type 2 diabetes therapy Ozempic®, which resulted in favorable confidential settlements on the eve of trial.
- Successful representation of Novo Nordisk in patent infringement lawsuits brought against six ANDA filers concerning Novo Nordisk’s weight-loss treatment Saxenda®.
- Represented Novo Nordisk in a series of Hatch-Waxman patent litigations relating to its blockbuster type 2 diabetes drug Victoza®. Prevailing in claim construction proceedings helped lead to favorable confidential settlements in each matter.
- Represented Pfizer and UCB in a series of District Court and PTAB trials concerning the drug Toviaz®. In the first trial against five defendants, the District Court ruled in Pfizer and UCB’s favor on all issues. In the second trial, the District Court ruled in Pfizer and UCB’s favor on all issues immediately upon the close of evidence. The PTAB upheld all challenged claims and the Federal Circuit affirmed.
- Represented Novo Nordisk as patent owner in an inter partes review filed by a competitor concerning methods of nanofiltering recombinant therapeutic proteins. The PTAB upheld all challenged claims in Novo Nordisk’s patent.
- Represented Swiss biopharmaceutical company IBSA in Hatch-Waxman litigations concerning its products Flector® and Tirosint®.
- Successful trial and appellate representation of UCB in a suit brought by generic manufacturer Apotex, alleging that UCB’s Univasc® and Uniretic® high blood pressure medications infringed Apotex’s patented method of manufacture. The district court found in UCB’s favor on all defenses, including inequitable conduct. The Federal Circuit affirmed unanimously, and the district court awarded UCB its legal fees.
*Includes experience from a previous firm
Recognition Recognition Recognition
Recognition Recognition Recognition
The Legal 500
2023
Recognized for Patent Litigation
Patexia
2023
Recognized among the Top ANDA Attorneys
The Legal 500
2023
Recognized for Patent Litigation
Patexia
2023
Recognized among the Top ANDA Attorneys